Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 1/2015

01-11-2015 | Epidemiology

onlineDeCISion.org: a web-based decision aid for DCIS treatment

Authors: Elissa M. Ozanne, Katharine H. Schneider, Djøra Soeteman, Natasha Stout, Deborah Schrag, Michael Fordis, Rinaa S. Punglia

Published in: Breast Cancer Research and Treatment | Issue 1/2015

Login to get access

Abstract

Women diagnosed with DCIS face complex treatment decisions and often do so with inaccurate and incomplete understanding of the risks and benefits involved. Our objective was to create a tool to guide these decisions for both providers and patients. We developed a web-based decision aid designed to provide clinicians with tailored information about a patient’s recurrence risks and survival outcomes following different treatment strategies for DCIS. A theoretical framework, microsimulation model (Soeteman et al., J Natl Cancer 105:774–781, 2013) and best practices for web-based decision tools guided the development of the decision aid. The development process used semi-structured interviews and usability testing with key stakeholders, including a diverse group of multidisciplinary clinicians and a patient advocate. We developed onlineDeCISion.​org to include the following features that were rated as important by the stakeholders: (1) descriptions of each of the standard treatment options available; (2) visual projections of the likelihood of time-specific (10-year and lifetime) breast-preservation, recurrence, and survival outcomes; and (3) side-by-side comparisons of down-stream effects of each treatment choice. All clinicians reviewing the decision aid in usability testing were interested in using it in their clinical practice. The decision aid is available in a web-based format and is planned to be publicly available. To improve treatment decision making in patients with DCIS, we have developed a web-based decision aid onlineDeCISion.​org that conforms to best practices and that clinicians are interested in using in their clinics with patients to better inform treatment decisions.
Literature
1.
Soeteman DI, Stout NK, Ozanne EM, Greenberg C, Hassett MJ, Schrag D, Punglia RS (2013) Modeling the effectiveness of initial management strategies for ductal carcinoma in situ. J Natl Cancer Inst 105(11):774–781PubMedCentralCrossRefPubMed
2.
Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. Cancer J Clin 63(1):11–30CrossRef
3.
Institute of Medicine (2009) Initial national priorities for comparative effectiveness research. National Academies Press, Washington, DC
4.
Bijker N, Meijnen P, Peterse JL, Bogaerts J, Van Hoorebeeck I, Julien JP, Gennaro M, Rouanet P, Avril A, Fentiman IS et al (2006) Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853—a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol 24(21):3381–3387CrossRefPubMed
5.
Fisher B, Land S, Mamounas E, Dignam J, Fisher ER, Wolmark N (2001) Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience. Semin Oncol 28(4):400–418CrossRefPubMed
6.
Emdin SO, Granstrand B, Ringberg A, Sandelin K, Arnesson LG, Nordgren H, Anderson H, Garmo H, Holmberg L, Wallgren A (2006) SweDCIS: radiotherapy after sector resection for ductal carcinoma in situ of the breast. Results of a randomised trial in a population offered mammography screening. Acta Oncol 45(5):536–543CrossRefPubMed
7.
Houghton J, George WD, Cuzick J, Duggan C, Fentiman IS, Spittle M (2003) Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet 362(9378):95–102CrossRefPubMed
8.
Wapnir IL, Dignam JJ, Fisher B, Mamounas EP, Anderson SJ, Julian TB, Land SR, Margolese RG, Swain SM, Costantino JP et al (2011) Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst 103(6):478–488PubMedCentralCrossRefPubMed
9.
Baxter NN, Virnig BA, Durham SB, Tuttle TM (2004) Trends in the treatment of ductal carcinoma in situ of the breast. J Natl Cancer Inst 96(6):443–448CrossRefPubMed
10.
Rakovitch E, Pignol JP, Chartier C, Hanna W, Kahn H, Wong J, Mai V, Paszat L (2007) The management of ductal carcinoma in situ of the breast: a screened population-based analysis. Breast Cancer Res Treat 101(3):335–347CrossRefPubMed
11.
Kerlikowske K, Molinaro AM, Gauthier ML, Berman HK, Waldman F, Bennington J, Sanchez H, Jimenez C, Stewart K, Chew K et al (2010) Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J Natl Cancer Inst 102(9):627–637PubMedCentralCrossRefPubMed
12.
Solin LJ, Gray R, Baehner FL, Butler S, Badve S, Yoshizawa C, Shak S, Hughes L, Sledge G, Davidson NE et al (2011) A quantitative multigene RT-PCR assay for predicting recurrence risk after surgical excision alone without irradiation for ductal carcinoma in situ (DCIS): a prospective validation study of the DCIS score from ECOG E5194. San Antonio Breast Cancer 71:S4–S6
13.
Solin LJ, Gray R, Baehner FL, Butler SM, Hughes LL, Yoshizawa C, Cherbavaz DB, Shak S, Page DL, Sledge GW Jr et al (2013) A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst 105(10):701–710PubMedCentralCrossRefPubMed
14.
Partridge A, Adloff K, Blood E, Dees EC, Kaelin C, Golshan M, Ligibel J, de Moor JS, Weeks J, Emmons K et al (2008) Risk perceptions and psychosocial outcomes of women with ductal carcinoma in situ: longitudinal results from a cohort study. J Natl Cancer Inst 100(4):243–251CrossRefPubMed
15.
Vicini FA, Recht A (2002) Age at diagnosis and outcome for women with ductal carcinoma-in situ of the breast: a critical review of the literature. J Clin Oncol 20(11):2736–2744CrossRefPubMed
16.
Ravdin PM, Siminoff IA, Harvey JA (1998) Survey of breast cancer patients concerning their knowledge and expectations of adjuvant therapy. J Clin Oncol 16(2):515–521PubMed
17.
Stacey D, Bennett CL, Barry MJ, Col NF, Eden KB, Holmes-Rovner M, Llewellyn-Thomas H, Lyddiatt A, Legare F, Thomson R (2011) Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev 5(10):CD001431
18.
Hoffman AS, Volk RJ, Saarimaki A, Stirling C, Li LC, Harter M, Kamath GR, Llewellyn-Thomas H (2013) Delivering patient decision aids on the Internet: definitions, theories, current evidence, and emerging research areas. BMC Med Inform Decis Mak 13(Suppl 2):S13PubMedCentralCrossRefPubMed
19.
Rippon I, Steptoe A (2015) Feeling old vs being old: associations between self-perceived age and mortality. JAMA Intern Med 175(2):307–309CrossRefPubMed
20.
Love N (2005) Management of breast cancer in the adjuvant and metastatic setts. Patterns Care Med Oncol 2(3)
21.
Peele PB, Siminoff LA, Xu Y, Ravdin PM (2005) Decreased use of adjuvant breast cancer therapy in a randomized controlled trial of a decision aid with individualized risk information. Med Decis Making 25(3):301–307CrossRefPubMed
22.
Bluman LG, Borstelmann NA, Rimer BK, Iglehart JD, Winer EP (2001) Knowledge, satisfaction, and perceived cancer risk among women diagnosed with ductal carcinoma in situ. J Women’s Health Gender-Based Med 10(6):589–598CrossRef
23.
van Gestel YR, Voogd AC, Vingerhoets AJ, Mols F, Nieuwenhuijzen GA, van Driel OJ, van Berlo CL, van de Poll-Franse LV (2007) A comparison of quality of life, disease impact and risk perception in women with invasive breast cancer and ductal carcinoma in situ. Eur J Cancer 43(3):549–556CrossRefPubMed
24.
Rakovitch E, Franssen E, Kim J, Ackerman I, Pignol JP, Paszat L, Pritchard KI, Ho C, Redelmeier DA (2003) A comparison of risk perception and psychological morbidity in women with ductal carcinoma in situ and early invasive breast cancer. Breast Cancer Res Treat 77(3):285–293CrossRefPubMed
25.
Jagsi R, Hayman J (2013) Informing patient decisions regarding management of ductal carcinoma in situ. J Natl Cancer Inst 105(11):758–759CrossRefPubMed
26.
Ozanne EM, Braithwaite D, Sepucha K, Moore D, Esserman L, Belkora J (2009) Sensitivity to input variability of the Adjuvant! Online breast cancer prognostic model. J Clin Oncol 27(2):214–219CrossRefPubMed
27.
Han PK (2013) Conceptual, methodological, and ethical problems in communicating uncertainty in clinical evidence. Med Care Res Rev 70(1 Suppl):14S–36SPubMedCentralCrossRefPubMed
28.
Partridge A, Winer JP, Golshan M, Bellon JR, Blood E, Dees EC, Sampson E, Emmons KM, Winer E (2008) Perceptions and management approaches of physicians who care for women with ductal carcinoma in situ. Clin Breast Cancer 8(3):275–280CrossRefPubMed
29.
Allegra CJ, Aberle DR, Ganschow P, Hahn SM, Lee CN, Millon-Underwood S, Pike MC, Reed SD, Saftlas AF, Scarvalone SA et al (2010) National institutes of health state-of-the-science conference statement: diagnosis and management of ductal carcinoma in situ September 22–24. J Natl Cancer Inst 102(3):161–169CrossRefPubMed
Metadata
Title
onlineDeCISion.org: a web-based decision aid for DCIS treatment
Authors
Elissa M. Ozanne
Katharine H. Schneider
Djøra Soeteman
Natasha Stout
Deborah Schrag
Michael Fordis
Rinaa S. Punglia
Publication date
01-11-2015
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2015
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-015-3605-y

Other articles of this Issue 1/2015

Breast Cancer Research and Treatment 1/2015 Go to the issue

Preclinical study

Prognostic and functional importance of the engraftment-associated genes in the patient-derived xenograft models of triple-negative breast cancers

Preclinical Study

Development of triple-negative breast cancer radiosensitive gene signature and validation based on transcriptome analysis

Preclinical study

Differential expression of epithelial–mesenchymal transition and stem cell markers in intrinsic subtypes of breast cancer

Epidemiology

The readability of online breast cancer risk assessment tools

Epidemiology

Hormone-related pathways and risk of breast cancer subtypes in African American women

Epidemiology

Myelodysplastic syndrome and acute myeloid leukemia following adjuvant chemotherapy with and without granulocyte colony-stimulating factors for breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits